IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Safety and Acceptability of a Vaginal Microbicide
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine the safety and acceptability of a vaginal microbicide in HIV uninfected sexually active women.
Study hypothesis: The vaginal microbicide 1% tenofovir will be safe and well tolerated in HIV uninfected women who are in good general health.
| Condition | Intervention | Phase |
|---|---|---|
| HIV Infections Hepatitis B, Chronic | Drug: 1% tenofovir gel | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Prevention |
| Official Title: | Phase II Expanded Safety and Acceptability Study of the Vaginal Microbicide 1% Tenofovir Gel |
- Macroscopic evidence of damage to the cervical, vulvar, or vaginal epithelium, including ulceration and other lesions, severe erythema, or severe edema, related or not related to the study gel or applicator
- Adherence to the study gel regimen
- acceptability of the study gel
| Enrollment: | 200 |
| Study Completion Date: | October 2007 |
While the male condom is effective in preventing sexual transmission of HIV, its use is hampered by deeply rooted cultural and social barriers. About half of all HIV infections worldwide occur in women, yet the only available female-controlled method of HIV prevention is the female condom. Alternative prevention tools, such as vaginal microbicides, are urgently needed to slow the rapid spread of heterosexual HIV infection.
This study will last 24 weeks, with an additional 10 weeks of follow-up for participants with chronic hepatitis B virus (HBV) infection. Participants will be randomly assigned to one of four arms. Arm A participants will insert a vaginal tenofovir 1% gel two hours prior to vaginal intercourse for a maximum of two daily applications. Arm B participants will insert a vaginal placebo gel two hours prior to vaginal intercourse for a maximum of two daily applications. Arm C participants will insert a vaginal tenofovir 1% gel once daily at bedtime or during the longest period of daily rest. Arm D participants will insert a vaginal placebo gel once daily at bedtime or during the longest period of daily rest.
A medical and menstrual history update, pregnancy test, HIV and sexually transmitted infections (STI) risk reduction counseling, and interview to assess behaviors toward vaginal gel use will occur during all study visits. HIV/STI counseling and testing, urinalysis, and blood collection will occur at study entry and at Week 24. Pelvic exam with colposcopy and vaginal swab collection will occur at study entry and Weeks 4, 12, and 24. For participants with chronic HBV, additional blood will be collected to monitor hepatitis B infection at study entry and Weeks 12, 24, 28, 32, and 36.
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- HIV uninfected
- Good general health
- Sexually active
- Willing to use acceptable methods of contraception, including male latex condoms for all acts of intercourse
- Willing to undergo all study-related assessments and adhere to the requirements of the study
Exclusion Criteria:
- Menopausal or postmenopausal
- Hysterectomy
- Abnormal screening results for several gynecologic exams
- Taking or planning to take tenofovir, adefovir, or any other medication for chronic HBV infection
- History of latex allergy
- History of adverse reaction to tenofovir or adefovir
- Use of a diaphragm or spermicide for contraception
- Prior participation in the study
- Prior participation in any vaginal microbicide, spermicide, or other drug study within 30 days of study entry
- Gynecologic surgical procedure within 90 days of study entry
- Illicit injection drug use within 12 months of study entry
- History of vaginal intercourse more than an average of two times per day in the two weeks prior to study screening
- Any other criteria that, in the investigator's opinion, may interfere with the study
- Current pregnancy or previous pregnancy within 90 days of study entry
- Breastfeeding
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00111943
| United States, Alabama | |
| Alabama Microbicide CRS | |
| Birmingham, Alabama, United States, 35294-0022 | |
| United States, New York | |
| Bronx- Lebanon Hospital Center Clinical Research Site (BLHC CRS) | |
| Bronx, New York, United States | |
| India | |
| NARI Arogya Aadhar Clinic CRS | |
| Pune, Maharashtra, India, 411002 | |
| Study Chair: | Sharon Hillier, PhD | Department of Obstetrics and Gynecology and Reproductive Sciences, Magee-Women's Hospital |
| Study Chair: | Jessica Justman, MD | Bronx-Lebanon Hospital Center |
| Study Chair: | Smita N. Joshi, MBBS | National AIDS Research Institute (NARI) |
| Study Chair: | Craig Hoesley, MD | University of Alabama at Birmingham |
More Information
Additional Information:
Publications:
| Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT00111943 History of Changes |
| Other Study ID Numbers: |
HPTN 059 10145 ( Registry Identifier: DAIDS ES ) |
| Study First Received: | May 26, 2005 |
| Last Updated: | March 26, 2012 |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
|
Anti-Infective Agents, Local HIV Seronegativity Tenofovir Vaginal gel |
Microbicide Vaginal Microbicide PMPA |
Additional relevant MeSH terms:
|
HIV Infections Hepatitis B Hepatitis B, Chronic Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Hepadnaviridae Infections DNA Virus Infections Hepatitis, Viral, Human |
Hepatitis Liver Diseases Digestive System Diseases Hepatitis, Chronic Tenofovir Anti-Infective Agents Antiviral Agents Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents Anti-HIV Agents |
ClinicalTrials.gov processed this record on July 27, 2017